Monitor for patent issuance, partnership announcements, or grant awards that would validate the TBI strategy. The core catalyst remains the PARAGON Phase 3 ALS trial — watch for enrollment updates or design optimization news from the FDA.
Price Chart
Executive Summary
NeuroSense Therapeutics filed a U.S. patent application covering PrimeC (ciprofloxacin + celecoxib) for traumatic brain injury (TBI), including concussion, blast-related injury, and CTE. The filing is an early-stage IP expansion — no clinical data, no issued patent, and no change to the core ALS program.
Key Facts
- Filed a U.S. patent application covering PrimeC for TBI, concussion, blast-related injury, and CTE
- If granted, patent expected to provide protection through 2047, subject to extensions
- No approved disease-modifying therapies exist for TBI
- ALS remains NeuroSense's primary development priority; TBI is a longer-term strategic expansion
- Company evaluating future TBI initiatives through collaborations, grants, and non-dilutive funding
- No clinical data, issued patent, or partnership announced in this filing
Financial Impact
No financial figures disclosed; patent filing is pre-revenue and pre-clinical for TBI
Risk Factors
- Patent may not issue or may be challenged, invalidated, or narrowed
- PrimeC may not demonstrate safety or efficacy in TBI
- No near-term revenue or partnership; dilution risk remains for ALS trial funding
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110516 |
| Document: ea0308988-6k_neurosense.htm | 0001213900-26-110516 |
| Document: 0001213900-26-110516-index-headers.html | 0001213900-26-110516 |
| Document: 0001213900-26-110516-index.html | 0001213900-26-110516 |
| Document: 0001213900-26-110516.txt | 0001213900-26-110516 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $2.67 $2.39 | ▼ −10.32% | ▼ −10.65% | $2.46 (−7.69%) |
Oct 13, 2026 13d ago | 6-K | $3.49 $3.06 | ▼ −12.32% | ▼ −11.24% | $2.46 (−29.51%) |
Sep 25, 2026 4w ago | 6-K | $5.10 $4.78 | ▲ +6.27% | ▲ +6.09% | $2.46 (+51.76%) |
Aug 6, 2026 11w ago | 6-K | $0.5030 $0.4999 | ▼ −0.62% | ▼ −1.23% | $2.46 (+389.07%) |
Jul 22, 2026 13w ago | 6-K | $0.6500 $0.6550 | ▲ +0.77% | ▲ +2.00% | $2.46 (+278.46%) |
Jun 29, 2026 17w ago | 6-K | $0.7099 $0.7200 | ▲ +1.42% | ▲ +0.64% | $2.46 (+246.53%) |
Jun 17, 2026 18w ago | Insider Cluster | $16.10 $15.78 | ▼ −1.99% | ▼ −1.67% | $2.46 (−84.72%) |
Jun 11, 2026 19w ago | 6-K | $0.7390 $0.7352 | ▼ −0.51% | ▼ −1.05% | $2.46 (+232.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers